Regardless of what’s happening elsewhere in the market, biopharma is a great place to look for stocks to pack into your portfolio because there’s always an illness that can be treated more effectively in the future than it is being treated today.
Our trade alert features an established drug maker with an excellent approval history. Their treatments have been widely trusted for years, and currently, they have multiple promising projects in the pipeline.
Drugmaker, Viatris (VTRS) is profitable and looking for more growth. The company is in the process of trimming its less-profitable operations, including its biosimilars, women’s health division, and its over-the-counter drugs. In its place, it is adding an ophthalmology franchise through the $750 million acquisitions of Oyster Point Pharma and Famy Life Sciences. The deal is expected to close in the first quarter of 2023. Management expects the acquisition to generate at least $1 billion in sales by 2028.
[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”VTRS” start_expanded=”true” display_currency_symbol=”true” api=”yf”]
You might also like:
- Elon’s Greatest Invention… Hidden in South Memphis?
- Controversial White House-backed energy find
- White House to reset Social Security?
- New discovery: 30,000 years of all-American energy?
- This robot is coming to 65 million Americans … this year.
- Where to invest $1,000 right now…
- The Most Exciting Human Discovery Since Fire?
- Wall Street Icon: “If you wait on this, it will already be too late”…
- Major DOGE Panic Begins, April 30?
- The DOGE Shock: Nine Stocks to Take Advantage of Elon’s Next Move
